PENUMBRA INC. overview

Penumbra, Inc. Announces Completion of Enrollment for Landmark STORM-PE Randomized Controlled Trial PR Newswire ALAMEDA, Calif., June 16, 2025 STORM-PE is a first-of-its-kind clinical trial comparing computer assisted vacuum thrombectomy (CAVT™) using Penumbra's Lightning Flash™ with anticoagulation versus anticoagulation alone in the treatment of acute intermediate-high risk pulmonary embolism ALAMEDA, Calif. , June 16, 2025 /PRNewswire/ -- Penumbra, Inc . (NYSE: PEN), the world's leading...

Penumbra, Inc. to Present at Upcoming Investor Conferences PR Newswire ALAMEDA, Calif., May 20, 2025 ALAMEDA, Calif. , May 20, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the following investor conferences on the dates and times listed below. Event: William Blair 45 th Annual Growth Stock Conference Date: Tuesday, June 3, 2025 Time: 3:00pm ET/12:00pm PT Event: Jefferies Global Healthcare Conference Date: Wednesday, June 4,...

Penumbra, Inc. to Present at the BofA Securities 2025 Health Care Conference PR Newswire ALAMEDA, Calif., April 29, 2025 ALAMEDA, Calif. , April 29, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025 . Event: BofA Securities 2025 Health Care Conference Date: Tuesday, May 13, 2025 Time: 6:00pm ET / 3:00pm PT A webcast of the presentation can be accessed on the...

Penumbra, Inc. Reports First Quarter 2025 Financial Results PR Newswire ALAMEDA, Calif., April 23, 2025 ALAMEDA, Calif. , April 23, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2025 . Revenue of $324.1 million in the first quarter of 2025, an increase of 16.3% or 16.9% in constant currency 1 , compared to the first quarter of 2024. U.S. Thrombectomy revenue of $187.9 million in...

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Penumbra, Inc. (NYSE: PEN) PR Newswire NEW YORK, April 8, 2025 NEW YORK , April 8, 2025 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Penumbra, Inc. (NYSE: PEN) on behalf of the company's shareholders. The investigation seeks to determine whether Penumbra's directors breached their fiduciary duties in connection with recent corporate actions. If you are a shareholder of Penumbra and are...

Penumbra, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call for April 23, 2025 PR Newswire ALAMEDA, Calif., April 3, 2025 ALAMEDA, Calif. , April 3, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2025 after market close on Wednesday, April 23, 2025 at 4:30 PM Eastern Time . A press release with first quarter 2025 financial results will be issued after market close that...

Penumbra, Inc. Announces Don Kassing will Retire from Board of Directors PR Newswire ALAMEDA, Calif., Feb. 21, 2025 ALAMEDA, Calif. , Feb. 21, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced today that after 17 years of distinguished service, Don Kassing has notified the company that he will retire from the board of directors effective April 1, 2025 . Kassing joined Penumbra's Board of Directors in 2008 and has served as Presiding Director...

Penumbra, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results PR Newswire ALAMEDA, Calif., Feb. 18, 2025 ALAMEDA, Calif. , Feb. 18, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the fourth quarter and full year ended December 31, 2024 . Financial Highlights: Adjusted revenue 1 of $321.3 million , excluding the $5.8 million impact of the Italian government's payback provision pertaining to prior years,...